Introduction
============

Acral melanoma (AM) is a rare subtype of melanoma in Caucasians, which accounts for only 5% [@B1]. However, the proportion of AM is more than 50% in the Asian populations [@B2]. For patients in stage II/III of AM, surgical resection and high-dose interferon (HD-IFN) adjuvant treatment, are the main therapeutic regimens [@B3]. However, validated molecular biomarkers for predicting outcomes in patients with AM undergoing HD-IFN adjuvant therapy are lacking. For patients in stage IV of AM, standard chemotherapy (dacarbazine) cannot significantly improve overall survival (OS) [@B4]. Recently, individualized targeted therapy targeting *BRAF* and *KIT* mutations and anti-checkpoint immunotherapy have improved the clinical outcome of patients with metastatic AM [@B5]-[@B8]. However, the frequencies of *BRAF* and *KIT* mutations in Chinese patients with AM are 15.5% and 11.9% [@B9], [@B10], respectively, which leaves more than 70% patients without validated targeted therapy. Furthermore, anti-immune checkpoint drugs against PD-1/PD-L1 and CTLA-4 did not showed high overall response rate (ORR) because of lack of proper predictive biomarkers [@B11], [@B12]. Therefore, identification and characterization of molecular prognostic biomarkers and their application in combination with traditional treatment are urgently required.

AURKA (Aurora kinase A) belongs to the Aurora kinase family, and encodes an evolutionarily conserved serine/threonine kinase. During mitosis, AURKA is involved in centrosome maturation and separation, as well as bipolar spindle formation, ensuring that chromosomes are properly segregated and cytokinesis is smoothly executed. Therefore AURKA plays an essential role in cell cycle. Overexpression and aberrant amplification of AURKA have been observed in several types of cancers, such as cancers of the breast, colon, ovary, and cutaneous melanoma [@B13]-[@B16]. Recent studies have shown that AURKA amplification and overexpression are associated with poor prognosis in diverse cancers [@B17]-[@B19]. Considering this, a series AURKA kinase inhibitors (AKIs) have been applied both in vivo and in vitro. More importantly, certain AKIs have yielded positive results in clinical trials [@B20]-[@B22]. A phase II clinical trial using alisertib, an investigational AURKA inhibitor, in patients with multiple advanced solid tumors showed that nine of 49 (18%) women with breast cancer and ten of 48 (21%) participants with small-cell lung cancer demonstrated a partial response [@B20]. However, it remains to be determined whether patients with *AURKA* copy gain will respond better to AURKA inhibitors.

A previous study showed that *AURKA* copy gain was detected in 37.5% (6/16) patients with AM [@B23]. However, the data was mainly derived from a small-cohort of Caucasian patients and was not verified in Asian patients with AM. More importantly, large-scale screening of*AURKA* copy gain in AM samples has not been reported.

In this study, we collected 472 melanoma tissue from patients with AM and examined the CN of *AURKA*. Thus, this study represents the first systematic analysis of *AURKA* CN in patients with AM. Survival analysis revealed that *AURKA* copy gain was significantly correlated with clinical outcome, indicating that *AURKA* copy gain could be an independent predictive factor for prognosis in patients with AM treated with HD-IFN.

Materials and Methods
=====================

Study populations
-----------------

From January 2005 to December 2015, 472 patients with pathological diagnosis of AM were recruited for this retrospective study from the Peking University Cancer Hospital. Two hundred and fifty-six out of 472 patients received HD-IFN adjuvant treatment as follows: 15 × 10^6^ U/m^2^ d1-5/w × 4w + 9 × 10^6^ U tiw × 48w. All clinical and pathological data were obtained after reviewing medical records, including age, sex, TNM (tumour-node-metastases) stage, thickness (Breslow), ulceration and survival (follow-up persisted until March 2017, or until the missing of follow-up or death of patients). Written informed consent was obtained from all participants. This study was approved by our Institutional Review Board and was conducted according to the Declaration of Helsinki Principles.

QuantiGenePlex DNA assay
------------------------

Tissue homogenates were prepared using the QuantiGene sample processing kit for 472 (1 sample per patient) formalin-fixed, paraffin-embedded tissues (FFPE; Panomics of Affymetrics, Santa Clara, CA, USA) according to the manufacturer\'s instructions. Briefly, 5 to 8 pieces of deparaffinized sections (4-10 μm) were incubated with 150 μl homogenizing solution supplemented with 1.5 μl proteinase K (50 μg/μl) at 65°C for 6 h. The tissue homogenate was separated from debris by brief centrifugation and transferred to a new tube.

The branched DNA (bDNA) assay was performed using the QuantiGenePlex DNA kit (Panomics) according to the manufacturer\'s instructions. Briefly, the homogenate DNA was sheared using Covaris S2 (Covaris, Woburn, MA, USA) with the following settings: duty cycle 5%, intensity 3, cycles/burst 200, 80 s. For each assay well, 40 μl homogenate was denatured with 2.5 M NaOH (final concentration 0.18 M) in the presence of a DNA probe. The neutralized tissue homogenate was transferred to each well of hybridization plates containing the working bead mix. All samples were in processed in duplicates. The hybridization plate was sealed and incubated at 54°C ± 1°C in shaking incubator (600 rpm) for 18-22 h. The unbound samples were washed away using the Bio-plex Pro II wash station (Bio-Rad, Hercules, CA, USA). Then, the beads were sequentially hybridized with DNA pre-amplifier, DNA amplifier, labelled probe and SAPE (streptavidin-conjugated R-phycoerythrin). Fluorescence intensities were measured using the Bio-plex 100 system (Bio-Rad).

The mean fluorescence intensities of the duplicates were calculated for all genes. Background values were subtracted from each probe set signal. Values of tested genes were normalized to the geometric means of *RPPH1*, *RPP30* and *RPLP0*. For each test gene, the normalized signal was divided by the signal of the reference DNA sample (G1521, Promega, Madison, WI, USA), and the values were multiplied by the known copy number (usually 2 copies) of each gene in the reference genome.

Immunohistochemistry
--------------------

FFPE tissue sections were examined by immunohistochemistry (IHC) using a polyclonal antibody against AURKA (Cell Signaling). A standard Strept-avidin horseradish immunoperoxidase method was used for AURKA staining. Primary antibodies were diluted in buffer containing 10% normal goat serum. The tissue sections were deparaffinized with Xylene for 30 min and rehydrated in decreasing concentrations of ethanol. Endogenous peroxidases were blocked with 30% H~2~O~2~ diluted in phosphate-buffered saline (PBS) for 15 min. For antigen retrieval, slides were heated in a pressure cooker in EDTA (pH 8.5) for 2 min and 30 s, followed by cooling to room temperature (RT) in the same buffer. For antigen blocking, the slides were blocked with normal goat serum with 1 h. After washing, slides were incubated with the primary antibody overnight at 4℃ (dilution 1:500). Three 5-minute washes in buffer were conducted after each incubation. The slides were then incubated with secondary antibody, anti-rabbit/mouse antibody (DAKO) (30 min at RT), followed by staining with AEC for 5-30 min at RT until coloration was achieved, counterstaining with hematoxylin followed by staining, and sealing with water-soluble encapsulating agent. Staining intensity and percentage were independently scored by three pathologists as 0, 1, 2, and 3 ("0" as negative, and "1", "2" and "3" as positive; typical staining is shown in Fig. [1](#F1){ref-type="fig"}), without the knowledge of the copy number variations in the sample.

RNA extraction and RT-RCR analysis
----------------------------------

Total RNA was isolated from FFPE tissue sections using an RNeasy Mini Kit (Qiagen, Germantown, MD, USA) according to the manufacturer\'s instructions. RNA was quantified by measuring the A260/A280 absorbance rations (Nano-Drop Technologies, Wilmington, DE). RNA quality was evaluated using a 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany). Total RNA was reverse transcribed to cDNA using a ReverTra Ace qRCR RT kit (TOYOBO), according to the manufacturer\'s protocol. AURKA mRNA level was evaluated by RT-PCR on a 7500 Fast Real-Time PCR system (Applied Biosystems, Foster City, CA, USA) using SYBR Green (Sangon Biotech, Shanghai, China) according to the manufacturer\'s instructions. Forward and reverse primer sequences were as follows: AURKA, 5\'-ATTGCAGATTTTGGGTGGT-3\' and 5\'-AAACTTCAGTAGCATGTTCCTGTC-3\'; GAPDH (internal control), 5\'-GAAGGTGAAGGTCGGAGTC-3\' and 5\'-GAAGATGGTGATGGGATTTC-3\'. The delta-Ct method was used to determine relative gene expression level.

Statistical analysis
--------------------

The association between *AURKA* copy gain and clinicopathlogic characteristics were analysed using the Pearson\'s χ^2^ test or Fisher exact test. For the survival analyses, OS and progression-free survival (PFS) were analysed using the Kaplan-Meier method with the log-rank test for assessing differences in survival probability between groups. For patients with AM treated with HD-IFN, Kaplan-Meier estimates of time-to-event relapse-free survival (RFS) were calculated. Log-rank tests were used to estimate the statistical significance between the time-dependent outcomes of RFS. The Cox regression model was used to evaluate the prognostic factors. Two-sided *P* values less than 0.05 were considered to be statistically significant. All statistical analyses were performed using the SPSS 16.0 software.

Results
=======

Patient characteristics
-----------------------

Four hundred and seventy-two patients with AM were included in this study and their clinicopathological characteristics are listed in Table [1](#T1){ref-type="table"}. The patients, 245 males (51.9%) and 227 females (48.1%), were aged 15 to 92 years (median age, 55.0 years). According to the American Joint Committee on Cancer classification, tumour thickness was classified as follow: \< 1 mm in 13 (2.8%) patients, 1-2 mm in 82 (17.4%) patients, 2-4 mm in 166 (35.2%) patients, and \> 4 mm in 193 (41.0%) patients. Three hundred and twenty (67.8%) patients showed ulceration at the time of diagnosis. Histological examination was performed on formalin-fixed tissues in all case, and tumours were diagnosed and classified according to the TNM classification. Briefly, there were 47 (10.0%) case of stage I, 145 (30.6%) cases of stage II, 123 (26.1%) cases of stage III, and 157 (33.3%) cases of stage IV.

AURKA CN
--------

The median *AURKA* CN in patients with AM was 1.67 (ranged from 0.22 to 8.04), which was not significantly affected by analysed clinicopathological characteristics (Table [1](#T1){ref-type="table"}). Using 2.0 copies as the cut-off in *AURKA* CN evaluation, gene copy gain was detected in 116 cases (24.6%), including 98 patients with 2.0 to 2.99 *AURKA* copies and the remaining 18 patients with 3.0 to 8.04 copies (data not shown).

In addition, we analysed the correlation of *AURKA* copy gain to the mutations of therapeutic targets (including *NRAS*, *BRAF*, *KIT* and *PDGFRA*) in AM (Table [2](#T2){ref-type="table"} and Fig. [2](#F2){ref-type="fig"}). Among the 116 AM samples with *AURKA* copy gain, 17 (15.7%), 18 (16.5%), 22 (20.2%) and 4 (3.7%) showed mutations of *NRAS*, *BRAF*, *KIT*, and *PDGFRA*, respectively. This indicated that *AURKA* copy gain may not be mutually exclusive to mutations in the well-established target genes. Further analysis of the incidence of *NRAS, BRAF, KIT* and *PDGFRA* mutation in the patients of our cohort showed no significant differences in gene mutation frequency between patients with and without *AURKA* copy gain.

Association between *AURKA* CN and AURKA expression levels
----------------------------------------------------------

To determine the association between *AURKA* CN and AURKA expression levels, FFPE tissue sections from 124 patients with AM were examined using IHC (Table [3](#T3){ref-type="table"}). Of the 124 samples analysed, the overall rate of detection of AURKA was 41.1%. For the 28 cases with *AURKA* copy gain, the detection rate for AURKA was 60.7%, which was significantly higher than that (35.4%) in cases (34/96) with normal *AURKA* CN.

In addition, we also examined AURKA mRNA expression levels of 124 AM patients. Relative AURKA mRNA expression ranged from 0.0298 to 8.574 (median, 0.219). When we dichotomized *AURKA* CN into gain and normal, AURKA mRNA expression level was higher in patients with *AURKA* copy gain than with normal *AURKA* CN (median mRNA: 0.155 vs. 0.645, *P* = 0.022; Fig. [S1](#SM0){ref-type="supplementary-material"}a). Furthermore, dividing into two subgroups according to the protein expression levels (negative and positive), AURKA mRNA median levels were 0.130 and 0.412, respectively. There was significant correlation between AURKA mRNA and protein expression (*P* = 0.014; Fig. [S1](#SM0){ref-type="supplementary-material"}b). These findings indicated that the gain in *AURKA* CN correlates with high levels of AURKA expression.

Prognostic significance of *AURKA* copy gain for overall survival and progression-free survival of patients with AM
-------------------------------------------------------------------------------------------------------------------

We analysed the prognostic significance of *AURKA* copy gain for OS and PFS. Survival data were collected for patients (n = 472) with AM. The median follow-up period was 29.3 (range: 0.9-136.0) months. We found that the median OS for patients with *AURKA* copy gain was significantly shorter than that for patients with normal *AURKA* CN (48.5 vs. 59.8 months; *P* = 0.022; Fig. [3](#F3){ref-type="fig"}a). In addition, patients with *AURKA* copy gain had a significantly shorter median PFS compared to those with normal *AURKA* CN (13.3 vs. 30.0 months; *P* \< 0.001; Fig. [3](#F3){ref-type="fig"}b).

To assess the prognostic value of *AURKA* copy gain during different clinical stages, we performed a stratified analysis by TNM stage (I/II and III/IV). Patients with*AURKA* copy gain had significantly shorter periods of PFS than those with normal *AURKA* CN at stage I/II and stage III/IV (*P* = 0.015 and *P* \< 0.001, respectively; Fig. [3](#F3){ref-type="fig"}d and [3](#F3){ref-type="fig"}f). However, the status of *AURKA* copy gain was not associated with OS in stage I/II and stage III/IV (*P* = 0.282 and *P* = 0.076, respectively; Fig. [3](#F3){ref-type="fig"}c and [3](#F3){ref-type="fig"}e).

Multivariate Cox regression analysis revealed that *AURKA* copy gain was an independent prognostic factor for PFS (HR: 1.98; 95% CI: 1.50-2.61; *P* \< 0.001; Table [4](#T4){ref-type="table"}). Among other clinicopathological factors, clinical stage was an independent prognostic factor for OS and PFS (Table [4](#T4){ref-type="table"}).

Predictive value of *AURKA* copy gain for outcomes in patients with AM undergoing high-dose interferon therapy
--------------------------------------------------------------------------------------------------------------

Two hundred and fifty-six out of 472 patients with AM received HD-IFN adjuvant treatment. We determined the relapse-free survival time (RFS) of these patients, which is defined as the time from the date of treatment to first recurrence (local or distant). The median RFS for patients with *AURKA* copy gain was significantly shorter than that for patients with normal *AURKA* CN (11.1 months vs. 30.0 months; *P* \< 0.001; Fig. [4](#F4){ref-type="fig"}a). We also analysed the association between *AURKA* copy gain and RFS during different clinical stages. Significant differences in RFS was observed between patients with *AURKA* copy gain and with normal *AURKA* CN in stage I/II or III/IV of the disease (*P* = 0.002 and *P* \< 0.001, respectively; Fig. [4](#F4){ref-type="fig"}b and [4](#F4){ref-type="fig"}c). Multivariate Cox regression analysis showed that *AURKA* copy gain was an independent prognostic factor for RFS (HR: 2.93; 95% CI: 2.01-4.27; *P* \< 0.001; Table [5](#T5){ref-type="table"}). Of other parameters, age and clinical stages were independent prognostic factors for RFS (Table [5](#T5){ref-type="table"}).

Discussion
==========

Owing to delayed detection and aggressive biologic behavior, patients with AM appear to have an overall worse prognosis than those with other cutaneous melanomas [@B24]. Therefore, novel molecular biomarkers that can improve the definition of prognosis and direct therapeutic regimen selection for AM are urgently required. To our knowledge, the current study is the first to investigate the association between *AURKA* CN and its prognostic significance in patients with AM on a large scale.

Data from two previous studies showed that the frequencies of *AURKA* copy gain in cutaneous melanoma and acral melanoma are 13.1% and 37.5% [@B16], [@B23], respectively. In our cohort, the frequency of *AURKA* copy gain in AM is 24.6% (116/472), which is significantly different from that observed in the previous study, possibly due to differences in methodology and scoring criteria. One group used fluorescence *in situ* hybridization (FISH) and defined 12.1% melanomas as *AURKA* FISH-positive, although the result strongly depended on the cut-off criteria applied [@B16]. In addition, the subtype bias between Caucasian and Asian patients with melanoma may be another reason for this variation.

In our study, Cox univariate and multivariate analysis indicated that *AURKA* copy gain is an independent prognostic factor for PFS, but not for OS. Further analysis was performed to determine the relationship between *AURKA* copy gain and subsets of patients in different clinical stages of the disease. *AURKA* copy gain was significantly associated with PFS but not OS in the stage I/II and stage III/IV subgroup. These data suggested that *AURKA* copy gain correlated with the recurrence or metastasis of AM, indicating a more aggressive phenotype. Some recent investigations indicated that AURKA could promote progression of epithelial-mesenchymal transition (EMT), leading to tumour metastasis [@B25]-[@B27]. Further investigations are required to determine the role of *AURKA* copy gain during AM recurrence or metastasis.

Overexpression and amplification of AURKA kinase are generally detected in various cancers, which are associated with poor prognosis [@B13]-[@B19]. However, the association between *AURKA* copy gain and AURKA mRNA/protein levels is not fully elucidated. In our cohort, the IHC and RT-PCR results suggested that *AURKA* copy gain correlates with high levels of AURKA expression. A recent study indicated that AURKA mRNA level was higher in breast cancer patients exhibiting *AURKA* amplification but no significant correlation was indicated between *AURKA* amplification and protein levels [@B28]. This suggested that *AURKA* copy gain correlates with AURKA expression to a certain extent. However, a comprehensive analysis of AURKA at the levels of gene expression, gene copy number and protein in melanoma is still required. Additionally, biochemical studies of *AURKA* copy gain may assist in ascertaining its functional effects.

Considering the prognostic significance of *AURKA* copy gain in patients with AM, *AURKA* copy gain may be a potent target for targeted therapy of AM. In preclinical trials, AKIs could suppress cell proliferation, migration, and invasion of cancer cells, inhibiting the progress and growth of many cancers including malignant melanoma [@B29]-[@B32]. Interestingly, certain AKIs have been used in clinical trials [@B20]-[@B22]. Alisertib, an AKI, was used successfully in phase III clinical trials in patients with different types of advanced cancer [@B20]. However, the status of *AURKA* CN in melanoma was not examined. Further investigations are required to evaluate the effect of AKIs on AM models with or without *AURKA* copy gain. Furthermore, a recent study revealed that AKIs could enhance the effects of BRAF and MEK inhibitors in melanoma treatment [@B33]. Therefore, AKI-based single or combinations therapy may provide a new strategy for the treatment of advanced AM.

Interferon was the only approved agent for the adjuvant treatment of melanoma before 2014. According to a meta-analysis of 17 randomized controlled trials (RCTs) involving 8122 patients with high-risk cutaneous melanoma, interferon adjuvant treatment showed significant DFS (HR = 0.82) benefit and marginal OS (HR = 0.89) benefit [@B34]. More importantly, clinical trials have demonstrated the success of HD-IFN adjuvant treatment for AM in Asian patients [@B35]. However, drug toxicity might influence the quality of life to certain extent. Therefore, new predictive factors are required to identify patients who can benefit maximally from the HD-IFN adjuvant treatment. In our study, Cox univariate and multivariate analysis indicated that *AURKA* copy gain was significantly associated with the outcome of patients treated with HD-IFN. Therefore, *AURKA* copy gain might be a predictive biomarker to expedite decisions on whether to receive HD-IFN adjuvant treatment or switch to alternative options. The AURKA kinase downregulates p53, via phosphorylation of both Ser215 and Ser315 residues [@B36], [@B37]. Previous studies revealed that IFN-mediated induction of p53 contributes to tumour suppression [@B38]. These studies explained why patients with normal *AURKA* CN benefitted partially from HD-IFN therapy. Further investigations are required to extensively explore the specific mechanisms.

Our study has one limitation. The current study is retrospective, and focused only on AM. Thus, prospective well-designed studies focused on various subtypes of melanoma are required.

In summary, we demonstrated that a small population (24.6%) of patients with AM contains *AURKA* copy gain. Our study also demonstrated that *AURKA* copy gain correlates with poor prognosis in AM. Furthermore, *AURKA* copy gain may be a useful biomarker to predict the outcome of interferon therapy in patients with AM.
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![Typical staining of AURKA proteins. The staining score for each sample, counting the intensity and density of the staining, was graded as 0, 1, 2, and 3 ("0" as negative, and "3" as the strongest; or "0" as negative, and "1", "2" and "3" as positive).](jcav09p1267g001){#F1}

![*AURKA* copy gain and MAPK pathway gene mutation pattern of AM (n=472). Patients harboring at least one gene mutation of *BRAF*, *KIT*, *NRAS*, *PDGFRA* and *AURKA* copy gain are presented.](jcav09p1267g002){#F2}

![Kaplan-Meier analysis of overall survival and progression-free survival of AM patients according to clinical stage and *AURKA* CN: (a and b) for the overall AM patients group, (c and d) for the patients with stage I/II group, and (e and f) for the patients with stage III/IV group.](jcav09p1267g003){#F3}

![Kaplan-Meier analysis of relapse-free survival of AM patients treated with HD-IFN according to clinical stage and *AURKA* CN: (a) for the overall AM patients treated with HD-IFN group, (b and c) for the patients with stage I/II group and stage III/IV group, respectively.](jcav09p1267g004){#F4}

###### 

Relationship between *AURKA* CN and patients\' clinicopathological characteristics.

  --------------------------------------------------------------------------------------------------------------------------------------------------
  Variable      Calculated *AURKA* CN in tumor tissue   Patient number with calculated *AURKA* CN                                         
  ------------- --------------------------------------- ------------------------------------------- ----------- ------------ ------------ ----------
  Total         472                                     1.67                                                    356 (75.4)   116 (24.6)   

  Age (years)                                                                                                                             

  \< 55         229 (48.5)                              1.71                                        0.226\*     172 (75.1)   57 (24.9)    0.878^+^

  ≥ 55          243 (51.5)                              1.61                                                    184 (75.7)   59 (24.3)    

  Gender                                                                                                                                  

  Female        227 (48.1)                              1.69                                        0.426\*     167 (73.6)   60 (26.4)    0.367^+^

  Male          245 (51.9)                              1.63                                                    189 (77.1)   56 (22.9)    

  Ulceration                                                                                                                              

  Yes           320 (67.8)                              1.68                                        0.243\*     239 (74.7)   81 (25.3)    0.305^+^

  No            139 (29.4)                              1.63                                                    110 (79.1)   29 (20.9)    

  Unknown       13 (2.8)                                                                                                                  

  Thickness                                                                                                                               

  \< 1 mm       13 (2.8)                                1.79                                        0.538^\#^   10 (76.9)    3 (23.1)     0.550^+^

  1-2 mm        82 (17.4)                               1.73                                                    66 (80.5)    16 (19.5)    

  2-4 mm        166 (35.2)                              1.6                                                     129 (77.7)   37 (22.3)    

  \>4 mm        193 (41.0)                              1.67                                                    141 (73.1)   52 (26.9)    

  Unknown\      18 (3.8)                                                                                                                  
  TNM stages                                                                                                                              

  I             47 (10.0)                               1,74                                        0.462^\#^   40 (85.1)    7 (14.9)     0.188^+^

  II            145 (30.6)                              1.71                                                    107 (73.8)   38 (26.2)    

  III           123 (26.1)                              1.63                                                    97 (78.9)    26 (21.1)    

  IV            157 (33.3)                              1.63                                                    112 (71.3)   45 (28.7)    
  --------------------------------------------------------------------------------------------------------------------------------------------------

\*Wilcoxon rank-sum test.

^\#^ Kruskal-Wallis rank test.

^+^Pearson chi-squared test.

###### 

Associations between *AURKA* CN and *NRAS*, *BRAF*, *KIT*, and *PDGFRA* gene mutation status.

  Gene status          Total        *AURKA* CN                
  -------------------- ------------ ------------ ------------ ---------
  *NRAS* mutations                                            
  Yes                  53 (11.2)    36 (67.9)    17 (32.1)    0.178\*
  No                   386 (81.8)   295 (76.4)   91 (23.6)    
  Unknown              33 (7.0)                               
  *BRAF* mutations                                            
  Yes                  67 (14.2)    49 (73.1)    18 (26.9)    0.608\*
  No                   380 (80.5)   289 (76.1)   91 (23.9)    
  Unknown              25 (5.3)                               
  *KIT* mutations                                             
  Yes                  77 (16.3)    55 (71.4)    22 (28.6)    0.381\*
  No                   365 (77.3)   278 (76.2)   87 (23.8)    
  Unknown              30 (6.4)                               
  *PDGFRA* mutations                                          
  Yes                  20 (4.2)     16 (80.0)    4 (20.0)     0.629\*
  No                   424 (89.8)   319 (75.2)   105 (24.8)   
  Unknown              28 (6.0)                               

\*Pearson chi-squared test.

###### 

Correlation of *AURKA* CN to AURKA expression.

  ----------------------------------------
  IHC score^a^        *AURKA* CN   
  ------------------- ------------ -------
  0                   11           62

  1                   10           21

  2                   5            8

  3\                  2\           5\
  Positive/total      17/28        34/96

  Positive rate (%)   60.7         35.4

  *P* value^b^        0.017^c^     \-
  ----------------------------------------

Abbreviations: CN, copy number; IHC, immunohistochemistry.

^a.^ Staining intensity and percentage were independently scored by three pathologists as 0, 1, 2, and 3 ("0" as negative, and "1", "2" and "3" as positive).

^b^ Significance evaluated by chi-square tests.

^c^ Positive rate of AURKA in cases with *AURKA* copy gain (CN \> 2.0) versus that in cases with normal *AURKA* CN (CN ≤ 2.0).

###### 

Univariate and multivariate analysis of prognostic factors for OS and PFS of patients with AM.

  Variable                      OS     PFS                                                                                                        
  ----------------------------- ------ ----------- ----------- ------ ----------- ----------- ------ ----------- ------------- ------ ----------- -------------
  Age (\<55 years/≥55 years)    1.10   0.80-1.48   0.591                                      0.99   0.77-1.28   0.929                            
  Gender (female/male)          1.04   0.76-1.43   0.788                                      1.15   0.89-1.49   0.274                            
  Ulceration (yes/no)           1.11   0.79-1.56   0.557                                      1.22   0.93-1.62   0.154                            
  Thickness (≤ 2 mm/\>2 mm)     0.80   0.57-1.12   0.196                                      0.83   0.63-1.09   0.181                            
  TNM stage (I + II/III +IV)    0.62   0.45-0.86   **0.004**   1.58   1.10-2.27   **0.012**   0.47   0.37-0.61   **\<0.001**   2.21   1.68-2.89   **\<0.001**
  *AURKA* CN (gain/normal)      1.54   1.06-2.22   **0.022**                      0.094       2.18   1.58-3.01   **\<0.001**   1.98   1.50-2.61   **\<0.001**
  *NRAS* mutations (yes/no)     1.81   1.12-2.92   **0.015**   1.65   1.10-2.47   **0.015**   1.25   0.81-1.94   0.313                            
  *BRAF* mutations (yes/no)     0.78   0.52-1.18   0.241                                      0.99   0.69-1.43   0.954                            
  *KIT* mutations (yes/no)      1.36   0.88-2.09   0.166                                      1.37   0.93-2.01   0.11                             
  *PDGFRA* mutations (yes/no)   1.24   0.54-2.84   0.616                                      1.12   0.59-2.11   0.737                            

HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; TNM, tumor-node-metastases.

The bold values refer to *P* \< 0.05.

###### 

Univariate and multivariate analysis of prognostic factors for RFS of AM patients treated with HD-IFN.

  Variable                      RFS                                                 
  ----------------------------- ------ ----------- ------------- ------ ----------- -------------
  Age (\<55 years/≥55 years)    1.25   0.89-1.76   0.192                            
  Gender (female/male)          1.16   0.83-1.62   0.391                            
  Ulceration (yes/no)           1.16   0.80-1.67   0.439                            
  Thickness (≤ 2 mm/\>2 mm)     0.64   0.45-0.91   **0.014**                        0.417
  TNM stage (I + II/III +IV)    0.37   0.26-0.52   **\<0.001**   2.72   1.91-3.88   **\<0.001**
  *AURKA* CN (gain/normal)      3.33   2.10-5.26   **\<0.001**   2.82   1.94-4.10   **\<0.001**
  *NRAS* mutations (yes/no)     1.24   0.69-2.22   0.469                            
  *BRAF* mutations (yes/no)     1.72   1.00-2.94   **0.051**                        0.344
  *KIT* mutations (yes/no)      1.14   0.70-1.85   0.61                             
  *PDGFRA* mutations (yes/no)   2.31   0.70-7.67   0.17                             

HR, hazard ratio; CI, confidence interval; RFS, relapse-free survival; TNM, tumor-node-metastases.
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